Topics
Glioblastoma | Treatment | Clinical trials | Ipilimumab
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Ipilimumab
Brown NF, McBain C, Brazil L,
Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C,
Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland
P.
Ipilimumab
with temozolomide vs. temozolomide alone after surgery and
chemoradiotherapy in recently diagnosed glioblastoma: a randomized
phase II clinical trial.
Neurooncol
Adv. 2025 May
26;7(1):vdaf032. doi:
10.1093/noajnl/vdaf032. PMID:
40800123. Interventional study. ˍ
ISRCTN.com
ID: ISRCTN84434175.
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
Ipilimumab; Nivolumab
Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD,
Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman
EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl
M, Galbraith K, Dignam JJ, Won M, Mehta MP.
Dual
Immune Check Point Blockade in MGMT-Unmethylated
Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized
Phase II/III Clinical Trial.
J
Clin Oncol. 2025 Aug 8:JCO2500618. doi:
10.1200/JCO-25-00618. PMID:
40779733. Interventional study. ˍ
NRGoncology.org
ID: NRG-BN007.